US Supreme Court Will Not Review Contrave Case
Teva’s Actavis Fails To Convince Top Court To Review Split Decision
The US Supreme Court has turned down a request by Teva’s Actavis to review a ruling that upheld a patent protecting Nalpropion’s Contrave until 2030, despite the generics firm pointing out that the exact terms of a patent claim were not present in its specification.
